CA2889697C - Cannabinoid receptor mediating compounds - Google Patents
Cannabinoid receptor mediating compounds Download PDFInfo
- Publication number
- CA2889697C CA2889697C CA2889697A CA2889697A CA2889697C CA 2889697 C CA2889697 C CA 2889697C CA 2889697 A CA2889697 A CA 2889697A CA 2889697 A CA2889697 A CA 2889697A CA 2889697 C CA2889697 C CA 2889697C
- Authority
- CA
- Canada
- Prior art keywords
- optionally
- substituted
- compound
- date received
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyrane Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261725949P | 2012-11-13 | 2012-11-13 | |
| US61/725,949 | 2012-11-13 | ||
| PCT/US2013/069686 WO2014078309A1 (en) | 2012-11-13 | 2013-11-12 | Cannabinoid receptor mediating compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2889697A1 CA2889697A1 (en) | 2014-05-22 |
| CA2889697C true CA2889697C (en) | 2023-03-14 |
Family
ID=49725346
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2889697A Active CA2889697C (en) | 2012-11-13 | 2013-11-12 | Cannabinoid receptor mediating compounds |
Country Status (7)
| Country | Link |
|---|---|
| US (6) | US9765031B2 (enExample) |
| EP (1) | EP2919779B1 (enExample) |
| JP (1) | JP6272626B2 (enExample) |
| CN (1) | CN104884057B (enExample) |
| CA (1) | CA2889697C (enExample) |
| IN (1) | IN2015DN03733A (enExample) |
| WO (1) | WO2014078309A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11155521B2 (en) * | 2012-11-13 | 2021-10-26 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Cannabinoid receptor mediating compounds |
| CA2889697C (en) | 2012-11-13 | 2023-03-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Cannabinoid receptor mediating compounds |
| CN106660968B (zh) * | 2014-05-09 | 2020-02-07 | 美国政府(由卫生和人类服务部的部长所代表) | 吡唑衍生物及其作为大麻素受体介体的用途 |
| WO2016196646A1 (en) * | 2015-06-04 | 2016-12-08 | The United States Of America, As Represented By The Secretary, Departmet Of Health & Human Services | Cannabinoid receptor mediating compounds |
| EP3423448B1 (en) * | 2016-03-04 | 2024-12-04 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Cannabinoid receptor mediating compounds |
| RU2703484C1 (ru) * | 2018-05-22 | 2019-10-17 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Саратовский государственный аграрный университет имени Н.И. Вавилова" | Способ производства безоболочных колбасок для функционального питания |
| CN115335361A (zh) * | 2020-03-24 | 2022-11-11 | 因弗萨戈制药公司 | 无定形3,4-二苯基-4,5-二氢-1h-吡唑衍生物的固体分散物、包括它们的组合物及其作为大麻素cb1受体抑制剂的用途 |
| CN115362146B (zh) * | 2020-04-07 | 2024-12-31 | 诺和诺德股份有限公司 | 用于生产4,5-二氢-1h-吡唑及中间体的方法 |
| EP4482490A4 (en) * | 2022-02-24 | 2025-08-20 | Novo Nordisk As | METHODS OF TREATING SUBJECTS WITH HYPERTRIGLYCERIDEMIA, ABDOMINAL OBESITY AND/OR ALTERED GLUCOSE |
| EP4493547A1 (en) * | 2022-03-14 | 2025-01-22 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Cannabinoid receptor modulating compounds |
| WO2025257151A1 (en) | 2024-06-10 | 2025-12-18 | Institut National de la Santé et de la Recherche Médicale | Methods and pharmaceutical composition for treating ciliopathies |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4675189A (en) | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
| JPS60100516A (ja) | 1983-11-04 | 1985-06-04 | Takeda Chem Ind Ltd | 徐放型マイクロカプセルの製造法 |
| CA1256638A (en) | 1984-07-06 | 1989-06-27 | Motoaki Tanaka | Polymer and its production |
| JP2551756B2 (ja) | 1985-05-07 | 1996-11-06 | 武田薬品工業株式会社 | ポリオキシカルボン酸エステルおよびその製造法 |
| JP2004500401A (ja) * | 2000-03-23 | 2004-01-08 | ソルベイ・フアーマシユーチカルズ・ベー・ブイ | Ｃｂ１−拮抗活性を有する４，５−ジヒドロ−１ｈ−ピラゾール誘導体 |
| ATE284872T1 (de) * | 2001-03-22 | 2005-01-15 | Solvay Pharm Bv | 4,5-dihydro-1h-pyrazolderivate mit cb1- antagonistischer wirkung |
| US6974810B2 (en) | 2001-09-21 | 2005-12-13 | Solvay Pharmaceuticals B.V. | 4,5-Dihydro-1H-pyrazole derivatives having potent CB1-antagonistic activity |
| ES2272809T3 (es) * | 2001-09-21 | 2007-05-01 | Solvay Pharm Bv | Nuevos derivados de 4,5-dihidro-1h-pirazol con actividad antagonista de cb1. |
| US20050239859A2 (en) * | 2003-09-03 | 2005-10-27 | Solvay Pharmaceuticals Gmbh | Novel medical uses of 4,5-dihydro-1h-pyrazole derivatives having cb1- antagonistic activity |
| ATE402697T1 (de) | 2004-01-30 | 2008-08-15 | Solvay Pharm Bv | 1,3,5-trisubstituierte 4,5-dihydro-1h-pyrazol- derivative mit cb1-antagonistischer aktivität |
| EP1574211A1 (en) * | 2004-03-09 | 2005-09-14 | Inserm | Use of antagonists of the CB1 receptor for the manufacture of a composition useful for the treatment of hepatic diseases |
| WO2006060192A2 (en) * | 2004-11-30 | 2006-06-08 | Bayer Pharmaceuticals Corporation | Pyrazole derivatives |
| JP5561720B2 (ja) | 2006-05-05 | 2014-07-30 | ジェンリン ディスカバリー | 肥満及び糖尿病を含む心臓血管障害を治療するために有用なカンナビノイド受容体アンタゴニスト／インバ−スアゴニスト |
| US7655685B2 (en) | 2007-11-02 | 2010-02-02 | Jenrin Discovery, Inc. | Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes |
| NZ585704A (en) | 2007-12-10 | 2012-08-31 | 7Tm Pharma As | Modulators of cannabinoid receptor CB1 for treating obesity |
| ES2540119T3 (es) | 2009-03-27 | 2015-07-08 | Abbvie Inc. | Compuestos como ligandos de receptores cannabinoides |
| US8217038B2 (en) | 2009-10-07 | 2012-07-10 | Jenrin Discovery, Inc. | Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes |
| EP2640381A4 (en) * | 2010-11-18 | 2014-05-21 | Jenrin Discovery | CANNABINOID RECEPTOR ANTAGONISTS / INVERSAGONISTS FOR THE TREATMENT OF METABOLISM DISEASES INCLUDING ADIPOSITAS AND DIABETES |
| US11155521B2 (en) * | 2012-11-13 | 2021-10-26 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Cannabinoid receptor mediating compounds |
| CA2889697C (en) | 2012-11-13 | 2023-03-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Cannabinoid receptor mediating compounds |
| CN106660968B (zh) | 2014-05-09 | 2020-02-07 | 美国政府(由卫生和人类服务部的部长所代表) | 吡唑衍生物及其作为大麻素受体介体的用途 |
| WO2016196646A1 (en) | 2015-06-04 | 2016-12-08 | The United States Of America, As Represented By The Secretary, Departmet Of Health & Human Services | Cannabinoid receptor mediating compounds |
-
2013
- 2013-11-12 CA CA2889697A patent/CA2889697C/en active Active
- 2013-11-12 IN IN3733DEN2015 patent/IN2015DN03733A/en unknown
- 2013-11-12 JP JP2015542015A patent/JP6272626B2/ja active Active
- 2013-11-12 EP EP13802153.0A patent/EP2919779B1/en active Active
- 2013-11-12 WO PCT/US2013/069686 patent/WO2014078309A1/en not_active Ceased
- 2013-11-12 US US14/442,383 patent/US9765031B2/en active Active
- 2013-11-12 CN CN201380069389.9A patent/CN104884057B/zh active Active
-
2017
- 2017-08-10 US US15/674,333 patent/US10787419B2/en active Active
- 2017-08-10 US US15/674,365 patent/US10683270B2/en active Active
-
2020
- 2020-05-08 US US16/870,093 patent/US11485709B2/en active Active
-
2022
- 2022-09-29 US US17/956,313 patent/US20230202983A1/en not_active Abandoned
-
2023
- 2023-02-10 US US18/108,264 patent/US11939297B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20230219896A1 (en) | 2023-07-13 |
| EP2919779B1 (en) | 2021-01-06 |
| US20160039766A1 (en) | 2016-02-11 |
| US10683270B2 (en) | 2020-06-16 |
| US11939297B2 (en) | 2024-03-26 |
| US9765031B2 (en) | 2017-09-19 |
| IN2015DN03733A (enExample) | 2015-09-18 |
| WO2014078309A8 (en) | 2015-05-21 |
| CN104884057A (zh) | 2015-09-02 |
| JP2015536997A (ja) | 2015-12-24 |
| CN104884057B (zh) | 2019-08-20 |
| US10787419B2 (en) | 2020-09-29 |
| JP6272626B2 (ja) | 2018-01-31 |
| US11485709B2 (en) | 2022-11-01 |
| CA2889697A1 (en) | 2014-05-22 |
| EP2919779A1 (en) | 2015-09-23 |
| US20180022706A1 (en) | 2018-01-25 |
| US20200331861A1 (en) | 2020-10-22 |
| US20180022705A1 (en) | 2018-01-25 |
| WO2014078309A1 (en) | 2014-05-22 |
| US20230202983A1 (en) | 2023-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11939297B2 (en) | Cannabinoid receptor mediating compounds | |
| US20190352268A1 (en) | Cannabinoid receptor mediating compounds | |
| AU2019227889B2 (en) | Pyrazole derivatives and their use as cannabinoid receptor mediators | |
| CN113831301A (zh) | 苯并噻唑类衍生物及其用途 | |
| US20220144776A1 (en) | Analogues of pentamidine and uses therefor | |
| EP3423448B1 (en) | Cannabinoid receptor mediating compounds | |
| US11155521B2 (en) | Cannabinoid receptor mediating compounds | |
| JP6906444B2 (ja) | 疾患および状態を処置するための組成物および方法 | |
| KR20230118883A (ko) | Enpp1 억제제로서의 이미다졸 화합물 | |
| HK1232213B (en) | Pyrazole derivatives and their use as cannabinoid receptor mediators |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20181109 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD Year of fee payment: 11 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241108 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241108 Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241108 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD Year of fee payment: 12 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251107 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251107 |